Adding Olaparib and Durvalumab Improved PFS in Patients Newly Diagnosed With Advanced Ovarian Cancer
Interim findings from the DUO-O trial could signal new options for women diagnosed with ovarian cancer at later stages who do not have a BRCA mutation. Patients newly diagnosed with advanced ovarian ...
MedPage Today on MSN
'Very Impressive' Survival With Combo in First-Line Prostate Cancer Study
Median overall survival with olaparib plus abiraterone reached 68 months in mid-stage tria ...
Please provide your email address to receive an email when new articles are posted on . Researchers reported statistically significant improvement in median PFS with the combination added to standard ...
Please provide your email address to receive an email when new articles are posted on . Olaparib monotherapy appeared well-tolerated and demonstrated evidence of antitumor activity among patients with ...
In mCRPC patients with BRCA1/2 or ATM alterations, first-line treatment with abiraterone plus prednisone and olaparib improves OS.
ASCO officials characterized the results as practice changing and said they highlighted the need for genetic testing in patients who receive a diagnosis of high-risk breast cancer. Giving olaparib to ...
FDA fast track covers ART6043 plus olaparib in PARP inhibitor–naïve gBRCAm, HER2-negative locally advanced/metastatic breast ...
The National Institute for Health and Care Excellence (NICE) has recommended the use of olaparib (Lynparza) for BRCA-mutated early breast cancer and hormone-relapsed metastatic prostate cancer ...
Outcomes of patients with T1a,b N0 Her2-positive breast cancer treated with adjuvant trastuzumab in a prospective registry in Ontario, Canada. This is an ASCO Meeting Abstract from the 2022 ASCO ...
SAN FRANCISCO -- Adding the PARP inhibitor olaparib (Lynparza) to standard-of-care abiraterone (Zytiga) as initial treatment for metastatic castration-resistant prostate cancer (mCRPC) extended median ...
Credit: Getty Images. This HRQoL analysis can help inform discussions of the benefit-risk profile of olaparib plus abiraterone. Adding olaparib to abiraterone does not clinically worsen health-related ...
The sNDA is supported by data from the phase 3 PROpel trial which included adults with mCRPC in the first-line setting. The Food and Drug Administration (FDA) has accepted for Priority Review the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results